Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - ALBANY MOLECULAR RESEARCH INCv312327_ex99-1.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________________

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 4, 2012

ALBANY MOLECULAR RESEARCH, INC.
(Exact Name of Registrant as Specified in Charter)

Delaware 000-25323 14-1742717
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

 

21 Corporate Circle, P.O. Box 15098, Albany, NY 12212
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (518) 512-2000

 (Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below) :

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

 

(d) On May 4, 2012, the Board of Directors of Albany Molecular Research, Inc. (the "Company") increased the number of members of the Board of Directors from seven to eight and appointed William S. Marth to serve as a Class II Director until the 2015 annual meeting of stockholders. The Company issued a press release announcing the appointment of Mr. Marth, the full text of which is furnished as Exhibit 99.1 hereto.

 

Item 9.01.        Financial Statements and Exhibits

 

(d) Exhibits.
   
99.1 Press Release dated May 7, 2012 issued by Albany Molecular Research, Inc.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 8, 2012 ALBANY MOLECULAR RESEARCH, INC.
     
  By: /s/ Mark T. Frost
    Name: Mark T. Frost
    Title: Senior Vice President, Administration,
    Chief Financial Officer and Treasurer

 

 
 

 

EXHIBIT INDEX

 

Exhibit
No.
  Description
99.1   Press Release dated May 7, 2012 issued by Albany Molecular Research, Inc.